KRAS-533 is a potent agonist of KRAS that binds to the GTP/GDP-binding pocket and prevents the hydrolysis of GTP, leading to accumulation of active GTP-bound KRAS. This triggers both apoptotic and autophagic cell death pathways in cancer cells, leading to potent suppression of mutant KRAS lung cancer in vitro and in animal models.

GNF362 is a highly selective and potent orally available inhibitor of inositol trisphosphate 3’ kinase B (Itpkb) with an IC50 of 9 nM, it also inhibits Itpka and Itpkc with IC50 values of 20 nM and 19 nM, respectively. It can be used in research to study treatment for T cell-mediated autoimmune diseases.

CL075 (3M002) is a selective agonist of TLR8 with immunomodulatory properties. It primes human neutrophils by activating signaling pathways, including p47phox phosphorylation and p38MAPK, leading to enhanced reactive oxygen species (ROS) production and contributing to immune defense.

CL075 (3M002) is a selective agonist of TLR8 with immunomodulatory properties. It primes human neutrophils by activating signaling pathways, including p47phox phosphorylation and p38MAPK, leading to enhanced reactive oxygen species (ROS) production and contributing to immune defense.

GNF362 is a highly selective and potent orally available inhibitor of inositol trisphosphate 3’ kinase B (Itpkb) with an IC50 of 9 nM, it also inhibits Itpka and Itpkc with IC50 values of 20 nM and 19 nM, respectively. It can be used in research to study treatment for T cell-mediated autoimmune diseases.

GNF362 is a highly selective and potent orally available inhibitor of inositol trisphosphate 3’ kinase B (Itpkb) with an IC50 of 9 nM, it also inhibits Itpka and Itpkc with IC50 values of 20 nM and 19 nM, respectively. It can be used in research to study treatment for T cell-mediated autoimmune diseases.

2-APQC is a potent activator of SIRT3 with a Kd value of 2.756 μM. It alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis, exhibiting promising cardioprotective potential in vitro and in vivo. It may serve as a potential candidate for future heart failure (HF) therapeutics.

2-APQC is a potent activator of SIRT3 with a Kd value of 2.756 μM. It alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis, exhibiting promising cardioprotective potential in vitro and in vivo. It may serve as a potential candidate for future heart failure (HF) therapeutics.

GNF362 is a highly selective and potent orally available inhibitor of inositol trisphosphate 3’ kinase B (Itpkb) with an IC50 of 9 nM, it also inhibits Itpka and Itpkc with IC50 values of 20 nM and 19 nM, respectively. It can be used in research to study treatment for T cell-mediated autoimmune diseases.

Sunvozertinib (DZD9008) is an oral, potent, and selective inhibitor of ErbBs (EGFR or Her2), particularly mutant forms of ErbBs. It also inhibits EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, Her2 exon 20 YVMA, and EGFR WT A431, with IC50 values of 20.4 nM, 20.4 nM, 1.1 nM, […]